SequelSEC

Nautilus Biotechnology, Inc. NAUT

Laboratory Analytical Instruments · CIK 0001808805 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
-$51.97M
Fiscal year ended 2025-12-31

Nautilus Biotechnology, Inc. (NAUT) reported net income of -$59.00M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Nautilus Biotechnology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

Nautilus Biotechnology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$59.00M-$70.78M-$63.68M-$57.92M-$50.32M-$15.62M
Research & development$41.11M$50.48M$47.25M$37.67M$29.35M$12.43M
Weighted-average diluted sharesshares 126.26Mshares 125.43Mshares 124.92Mshares 124.59Mshares 84.46Mshares 29.09M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0
Diluted EPS$-0.47$-0.56$-0.51$-0.46$-0.60$-0.54
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$25.73M$31.00M$28.90M$25.95M$21.15M$3.31M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Nautilus Biotechnology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$12.39M$27.65M$19.40M$114.52M$185.62M$36.61M
Total assets$191.11M$242.74M$305.56M$350.05M$398.45M$85.01M
Current assets$105.96M$132.83M$176.84M$187.21M$349.22M$77.66M
Total liabilities$34.14M$34.01M$40.21M$35.13M$34.87M$6.31M
Current liabilities$7.95M$7.63M$9.12M$6.79M$5.81M$3.02M
Total equity incl. NCI$156.97M$208.73M$265.35M$314.92M$363.58M-$29.72M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$140.24M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$943.00K$987.00K$1.64M$1.27M$1.72M$470.00K

Cash flow

Nautilus Biotechnology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$50.70M-$59.14M-$51.71M-$45.81M-$39.24M-$14.00M
Capital expenditures$1.28M$2.12M$2.44M$2.32M$2.27M$921.00K
Investing cash flow$35.22M$66.25M-$43.74M-$25.74M-$138.96M-$25.28M
Financing cash flow$214.00K$1.14M$368.00K$562.00K$327.45M$75.90M
Net change in cash-$15.26M$8.25M-$95.08M-$70.98M$149.24M$36.62M
Stock-based compensation$6.84M$12.70M$12.14M$10.38M$7.93M$369.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Nautilus Biotechnology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$51.97M-$61.27M-$54.15M-$48.13M-$41.51M-$14.92M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio13.33x17.40x19.39x27.57x60.09x25.73x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NAUT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-28View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-04-29View SEC filing

Companies in the same industry

A ASTC AVTR BFNH BIO BNGO BRKR CTKB EYPT HBIO ILMN LCTC

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 31818730 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.